K-pop

Artemis, Ahead of World Tour, Makes Comeback Today with New Album 'Hyper-Ego'

Six Songs, Including "Bon Stunner" and "Blue Blood" First Concert of Tour to Be Held at Yes24 Live Hall Next Month

KIM HYUNSIK
2026-08-07 13:56:58
[Edaily Starin KIM HYUNSIK Reporter] Girl group ARTMS made their comeback on the 7th with their new album "Hyper-ego."
(Photo courtesy of Mode House)
"Hyper-ego" consists of a total of six tracks, including the double title tracks "Born Stunner" and "Blue Blood," as well as "From Wings To Soul," 'Icarus Gang,' 'Hyper Crush,' and 'Pixel Memory.' All tracks were released at 1:00 p.m. that day via various online music platforms.
Among the double title tracks, “Born Stunner” blends a heavy bass drop, dynamic rhythmic shifts, powerful rap, and an addictive hook. This track was previously unveiled as a pre-release on the 24th of last month.
The other title track, “Blue Blood,” combines elements of hyperpop and J-Core, weaving Artemis’s group narrative into the lyrics under the theme of “blue rain.”
Their agency, Mode House, stated, “This album builds on the group’s narrative established through their previous releases, ‘Virtual Angel’ and ‘Icarus,’ while delivering the message that ‘everything, including love, could be fake’ and posing the bold question, ‘What is real?’”
Artemis unveiled their performance of “Born Stunner” on Mnet’s “M Countdown” yesterday. They will kick off their new world tour, “Art of BLUE BLOOD,” on the 5th and 6th of next month at the Yes24 Live Hall in Gwangjang-dong, Gwangjin-gu, Seoul.

Economy

Corporation

IT·Science

Economy

[Market In] E-Land World Moves to Issue 40 Billion Won in Corporate Bonds, Defying the BBB-Rating Downturn

E-Land World (BBB0) is set to issue up to 40 billion won in public corporate bonds. With investor sentiment toward BBB-rated corporate bonds currently subdued, all eyes are on whether the company can …
2026-08-07 18:54:04

Corporation

MedPacto, Inc. Adds Medium-Dose Group to Phase 2 Trial of Baekto-Seetip for Osteosarcoma… Files Application to Amend IND

(Photo courtesy of MedPacto, Inc.) MedPacto, Inc.(235980)is adding a medium-dose patient group to the Phase 2 clinical trial of “Vactosertib,” which it is developing as a treatment for osteosarcom…
2026-08-07 18:21:02

IT·Science

Coreline Soft Co., Ltd. Signs Contract for Lung Cancer Screening Project in Germany… A 10-Year “Jackpot”

Medical artificial intelligence (AI) company Coreline Soft Co., Ltd.(384470)announced on the 7th that it has secured a contract for a lung cancer screening project in Lostau, Germany, through Canon Me…
2026-08-07 18:44:02